Clinical Trial Update: Study Efficacy and Safety of INC280 in Patients With Advanced Hepatocellular Carcinoma. [Phase 2]

View source ↗

Summary

A Phase 2 trial of INC280 in advanced hepatocellular carcinoma with c-MET dysregulation was terminated; results assessing efficacy and safety have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Capmatinib (capmatinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Advanced Hepatocellular Carcinoma With c-MET Dysregulation | Phase 2 | Status: TERMINATED | Results posted: 2024-09-24